Antiangiogenic Agents in Cancer Therapy

1. Front Matter

   Pages i-xi

   PDF

2. Antiangiogenic Factors and Tumor Vasculature

   1. Front Matter

      Pages 1-1

      PDF

   2. Angiogenesis and Oxygen Transport in Solid Tumors

      • Zishan A. Haroon, Kevin G. Peters, Charles S. Greenberg, Mark W. Dewhirst

      Pages 3-21

   3. Oxygenation of Solid Tumors in Animals and Patients

      • Eric Lartigau, Marcelle Guichard

      Pages 23-35

   4. Role of Inflammatory Mediators in Angiogenesis

      • Federico Bussolino, Alberto Mantovani

      Pages 37-50

   5. Intra- and Extracellular pH in Solid Tumors

      • Chang W. Song, HeonJoo Park, Brian D. Ross

      Pages 51-64

   6. Contribution of the Extracellular Matrix and Macrophages in Angiogenesis

      • Peter J. Polverini

      Pages 65-75

   7. Regulation of Angiogenesis by the Organ Microenvironment

      • Diane R. Bielenberg, Isaiah J. Fidler

      Pages 77-91

   8. Fibroblast Growth Factors in Tumor Progression and Angiogenesis

      • Israel Vlodavsky, Gerhard Christofori

      Pages 93-118

   9. Role of Vascular Endothelial Growth Factor in Regulation of Angiogenesis

      • Napoleone Ferrara

      Pages 119-141

   10. Regulatory Aspects of Neovascularization

       • M. Zamirul Hussain, Q. Perveen Ghani, John J. Feng, Thomas K. Hunt

       Pages 143-150

3. Antiangiogenic Agents

   1. Front Matter

      Pages 151-151

      PDF

   2. Squalamine

      • Jon I. Williams

      Pages 153-174

   3. Cartilage as a Source of Natural Inhibitors of Angiogenesis

      • Vincent Castronovo, Violetta Dimitriadou, Pierre Savard, Marc Rivière, Eric Dupont

      Pages 175-183

   4. Thrombospondin as an Inhibitor of Angiogenesis

      • David W. Dawson, Noël P. Bouck

      Pages 185-203

   5. Matrix Metalloproteinase Inhibitors

      • Peter D. Brown, Mark Whittaker

      Pages 205-223

   6. Angiostatin Protein and Other Plasminogen Fragments

      • B. Kim Lee Sim

      Pages 225-236

   7. Dietary and Nutritional Modulation of Tumor Angiogenesis

      • Purna Mukherjee, Jin-Rong Zhou, Alexander V. Sotnikov, Steven K. Clinton

      Pages 237-261

   8. Thalidomide and Analogs

      • Taturo Udagawa, Henk M. W. Verheul, Robert J. D’Amato

      Pages 263-274

4. In Vivo Studies and Clinical Trials

   1. Front Matter

      Pages 275-275

      PDF

Beverly Teicher and a panel of distinguished investigators survey the state-of-the-art of antiangiogenesis research from the lab bench to clinical trials. Timely and authoritative, the contributors summarize our current understanding of tumor growth and its dependence on vascular development, as well as the present status of antiangiogenic agents in preclinical and clinical development. In addition, the book also examines what is known about the mechanisms by which these therapeutic agents interfere with tumor vasculature and grapples with the problem of establishing criteria by which to assess their clinical efficacy. Antiangiogenic Agents in Cancer Therapy offers a unique cutting-edge compendium of antiangiogenic research, taking stock of what has been accomplished , where the experimental therapeutics of antiangiogenic agents is going, and the continuing evolution of their role in cancer treatment and novel drug development.

• angiogenesis
• cancer
• cancer treatment
• clinical trial
• interferon
• macrophages
• tumor
• tumor growth
• tumor progression
• surgical oncology

• Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, USA

  Beverly A. Teicher

Policies and ethics